Get to know our clinical trials

Trial of selinexor, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MMRR)

THE OBJECTIVE OF THIS CLINICAL TRIAL IS TO COMPARE AND EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE, COMPARED TO THE EFFICACY AND SAFETY OF THE REFERENCE TREATMENT WITH ELOTUZUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE III, RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE AND DEXAMETHASONE (SPD) VERSUS ELOTUZUMAB, POMALIDOMIDE AND DEXAMETHASONE (ELOPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MMRR). IMMUNOTHERAPY
  • Code EudraCT: 2021-001691-41
  • Protocol number: EMN29
  • Promoter: European Myeloma Network (EMN)
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.